This is WeedWeek, because cannabis news matters.
Would you appreciate a WeedWeek regional supplement with more news from
? Or more news about the
? Sign up at the appropriate link.
Want to advertise in WeedWeek? Contact Adrienne Nascimento at email@example.com.
Note to readers: WeedWeek is now on Patreon, a way for your small monthly contributions to support WeedWeek and my reporting on the industry.
It works like NPR: The newsletter will remain free, but small contributions will enable readers to participate in our mission to offer credible, well-informed cannabis journalism.
Starting at just $2 a month, we're offering some fun perks and swag.
Starting at $50 a month you can promote yourself and your organization's brand in the newsletter every week.
As with advertisers, Patreon contributors will have no influence on WeedWeek's editorial content or on the pieces I write for other publications.
Here's the news:
Rolling Stone looks into the Senate’s bipartisan push to pass the CARERS Act, which would force the federal government to respect state MED laws. Sponsors include Democrats Cory Booker (N.J.), Al Franken (Minn.) and Kirsten Gillibrand (N.Y.) and Republicans Rand Paul (Ky.), Mike Lee (Utah) and Lisa Murkowski (Ak.). For more see here.
The 49-member Congressional Black Caucus declined to meet with President Trump, citing U.S. Attorney General Jeff Sessions’ efforts to “accelerate the failed war on drugs,” among other factors.
The Massachusetts Senate passed a bill to revise the voter-passed REC law. A journalist said cannabis activists should stop complaining and “chill out” over proposed changes, such as higher taxes. The state may also eliminate protections for people of color who want to join the industry.
After much back and forth, Vermont House Republicans blocked REC during a special legislative session. Gov. Phil Scott (R) said passing REC “wasn’t a priority for me.” The issue is likely to come up again in next year.
Nevada regulators want REC to be available July 1 despite a lawsuit from liquor wholesalers. The state’s powerful gaming industry has thus far declined to participate in the industry, but it wants to learn more.
Ohio Congressman Bob Gibbs (R) has repeatedly spoken up for MED but votes against it.
The Morning Call explains the MED situation in Pennsylvania. Philadelphia feels overlooked.
Dispensaries are confronting more grassroots opposition in San Francisco. Los Angeles is struggling to regulate its large market.
Canada is sticking to its goal to make REC available by July 2018.
Americans don’t mind if reporters use cannabis, according to a poll.
A Tampa strip club impresario and lung cancer patient is suing the state to grow his own MED.
Cuba says the movement toward legalization increases drug smuggling and said it would not liberalize its cannabis laws. The U.S. and Cuba are still collaborating to crack down on trafficking despite a chill in relations under President Trump.
In Poland, lawmakers voted to legalize MED. In Ireland, MED has run into political headwinds.
Seattle mayoral candidates discussed their favorite strains.
MJ Freeway, a software firm for cannabis businesses, suffered its second security breach in six months, when some of its source code was posted online. MJ Freeway called it a “theft” but said its data would not be affected. In January its system suffered a minor crash which it called a criminal attack.
Despite these setbacks, MJ Freeway is on a good run. It recently won contracts to track inventory for the governments of Washington and Pennsylvania.
A new “self-regulatory” group called the National Association of Cannabis Businesses, wants to create national standards for the industry.
Citing fears of a Justice Department crackdown, PNC Bank said it will close pro-legalization group MPP’s 22 year old bank accounts.
The Guardian finds that commercial cultivation has a heavy environmental cost.
Louisiana State University will earn at least $3.4M over five years from a MED production deal.
Colorado’s cannabis producer tax has reached the historic low of 43 cents per gram.
Buzzfeed goes inside the race to develop a weed breathalyzer.
The Winklevoss twins are being sued after allegedly pledging to invest almost $500,000 in weed delivery app Eaze.
Health and Science
Editorial: This week the U.S. Senate is expected to vote on a sweeping health care bill without public hearings. The best guess available is that it will leave 23 million more Americans uninsured. In exchange it will deliver large tax cuts to the wealthiest Americans. Vox found that eight Republicans who plan to vote for it can’t coherently defend it.
The Senate vote comes down to 10 key states: Alaska, West Virginia, Maine, Nevada, Arizona, Colorado, Ohio, Pennsylvania, Louisiana and Arkansas. All of those states have legalized MED or REC. Some have thriving industries.
In December I argued in Slate that the cannabis industry's unique history gives it a moral obligation to oppose the nomination of then Sen. Jeff Sessions (R) to U.S. Attorney General. No one listened. The industry's largest lobby, the National Cannabis Industry Association, took an accommodationist stance. If there was any significant dissent within the industry, I'm unaware of it.
The cannabis industry's ties to the health care issue are perhaps not as direct as they were to Sessions, but if this bill passes, it will hurt many of you and the ones you love. It will also hurt your customers, employees, colleagues, patients and friends.
Some cannabis people like to say they're building a "new kind of industry," one that cares about the world around it. In part that's because many involved in cannabis have fought for justice themselves and know from experience that authority can be ignorant and cruel. But for too many, doing the right thing translates into making or eating gluten-free edibles, rather than active struggle to achieve what's decent and right.
An industry effort to oppose this health care law is another opportunity for cannabis to prove that it's a new kind of industry. And if it misses enough opportunities, it will soon become a very familiar kind of industry.
To learn what you can do, go to Indivisible's TrumpCare Ten page.
To share this editorial on Facebook go here.
Two studies differed in their findings on whether legalization worsens road safety. One study found it did not change the number of fatalities, another study said it led to a three percent increase in crashes.
An Ohio coroner says he has seen cannabis mixed with the powerful synthetic opioid fentanyl, but the statement couldn’t be confirmed independently.
Science journalist Maia Szalavitz says pot addiction is real.
California doctors are seeing more pot-induced vomiting.
States remain skeptical about including opioid addiction as a qualifying condition for MED.
A Kentucky lawmaker says terminally-ill patients should have MED access.
Researcher’s at Lehigh University in Pennsylvania will study MED’s effect on autistic children.
On the podcast “Shaping Fire” neurologist Dr. Ethan Russo talks about medical uses for MED and psilocybin (the hallucinogen in mushrooms).
Parents worry that in the Trump era it may be harder to obtain MED to curtail children’s seizures.
Want to reach a devoted audience of top cannabis professionals? Advertise in WeedWeek. Contact Adrienne Nascimento at firstname.lastname@example.org for details.
Advertising policy: Advertisers and contributors through Patreon have no influence on WeedWeek's editorial content or on the content of articles that I write for other publications. In an effort to replicate the separation of business and editorial operations practiced at reputable news organizations, a WeedWeek salesperson will be responsible for all sales-related contact with advertisers and will work, as much as possible, without input from me. Any future advertising queries sent to me will be referred to a salesperson. In the newsletter, all ads and other forms of paid content will be clearly marked. I will not approach potential advertisers to solicit business, and reserve the right to reject ads if they present a conflict of interest, the appearance of a conflict of interest or for any other reason.
All rights reserved.